US FDA rejects sutimlimab for cold agglutinin disease (CAD)

The FDA rejection was due to deficiencies from a pre-license inspection of a third-party manufacturing facility. Sutimlimab, a monoclonal antibody targeting C1s (serine protease within the C1-complex) was expected to be the first treatment approved for the treatment of CAD.

Source:

Biospace Inc.